$BSGM
BioSig Technologies, Inc.

2023 Q2 Form 10-Q Financial Statement

#000118518523000516 Filed on May 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q4
Revenue $0.00 $5.000K $135.0K
YoY Change -100.0% -37.5% 1587.5%
Cost Of Revenue $27.00K
YoY Change
Gross Profit $108.0K
YoY Change 1250.0%
Gross Profit Margin 80.0%
Selling, General & Admin $9.107M $6.245M $5.903M
YoY Change 111.69% -2.44% -22.3%
% of Gross Profit 5465.74%
Research & Development $1.700M $1.100M $1.120M
YoY Change 21.43% -31.97% -17.28%
% of Gross Profit 1037.04%
Depreciation & Amortization $92.00K $84.00K $83.00K
YoY Change 29.58% 52.73% 48.21%
% of Gross Profit 76.85%
Operating Expenses $10.91M $7.391M $7.106M
YoY Change 90.57% -8.45% -21.11%
Operating Profit -$10.91M -$7.386M -$6.998M
YoY Change 90.83% -8.42% -22.24%
Interest Expense $3.000K $4.000K $2.000K
YoY Change
% of Operating Profit
Other Income/Expense, Net -$225.0K
YoY Change
Pretax Income -$11.13M -$7.382M -$6.996M
YoY Change 94.72% -8.47% -22.26%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$11.09M -$7.332M -$7.045M
YoY Change 92.62% -9.09% -18.5%
Net Earnings / Revenue -146640.0% -5218.52%
Basic Earnings Per Share -$1.58 -$1.19
Diluted Earnings Per Share -$0.16 -$0.12 -$0.14
COMMON SHARES
Basic Shares Outstanding 70.49M shares 66.86M shares 48.02M shares
Diluted Shares Outstanding 7.028M shares 6.187M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.354M $1.513M $458.0K
YoY Change -73.33% -82.54% -96.07%
Cash & Equivalents $1.300M $1.400M $400.0K
Short-Term Investments $102.0K $101.0K $101.0K
Other Short-Term Assets $423.0K $275.0K $325.0K
YoY Change -33.18% -11.58% -8.19%
Inventory $189.0K $345.0K $336.0K
Prepaid Expenses $418.0K $275.0K $325.0K
Receivables $21.00K $17.00K $9.000K
Other Receivables $5.000K $0.00 $0.00
Total Short-Term Assets $1.987M $2.150M $1.128M
YoY Change -74.31% -80.46% -91.88%
LONG-TERM ASSETS
Property, Plant & Equipment $621.0K $630.0K $665.0K
YoY Change 4.19% -46.38% 1.99%
Goodwill
YoY Change
Intangibles $1.000K $1.000K $1.000K
YoY Change 0.0% 0.0%
Long-Term Investments $69.00K $94.00K $120.0K
YoY Change
Other Assets $514.0K $244.0K $44.00K
YoY Change 1123.81% 480.95% 4.76%
Total Long-Term Assets $2.063M $3.047M $2.982M
YoY Change 11.27% 97.86% 83.51%
TOTAL ASSETS
Total Short-Term Assets $1.987M $2.150M $1.128M
Total Long-Term Assets $2.063M $3.047M $2.982M
Total Assets $4.050M $5.197M $4.110M
YoY Change -57.77% -58.56% -73.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $3.236M $2.713M $3.165M
YoY Change 80.58% 4.51% 28.55%
Deferred Revenue $8.000K $0.00
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.332M $2.814M $3.261M
YoY Change 75.46% 3.88% 26.59%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $282.0K $368.0K $452.0K
YoY Change -53.69% 15.72% 19.58%
Total Long-Term Liabilities $282.0K $368.0K $452.0K
YoY Change -53.69% 15.72% 19.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.332M $2.814M $3.261M
Total Long-Term Liabilities $282.0K $368.0K $452.0K
Total Liabilities $3.614M $3.182M $3.713M
YoY Change 44.1% 4.57% 25.69%
SHAREHOLDERS EQUITY
Retained Earnings -$234.4M -$223.3M -$216.0M
YoY Change 15.67% 14.32%
Common Stock $73.00K $67.00K $55.00K
YoY Change 62.22% 52.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $242.0K $1.976M $313.0K
YoY Change
Total Liabilities & Shareholders Equity $4.050M $5.197M $4.110M
YoY Change -57.77% -58.56% -73.52%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q4
OPERATING ACTIVITIES
Net Income -$11.09M -$7.332M -$7.045M
YoY Change 92.62% -9.09% -18.5%
Depreciation, Depletion And Amortization $92.00K $84.00K $83.00K
YoY Change 29.58% 52.73% 48.21%
Cash From Operating Activities -$4.895M -$5.600M -$4.114M
YoY Change -26.97% -5.74% -28.21%
INVESTING ACTIVITIES
Capital Expenditures $77.00K $45.00K $58.00K
YoY Change -1640.0% -181.82% -140.28%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$77.00K -$45.00K -$58.00K
YoY Change 1440.0% -18.18% -59.72%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.812M $6.748M 3.642M
YoY Change 54.23% 124.78% -364300.0%
NET CHANGE
Cash From Operating Activities -4.895M -$5.600M -4.114M
Cash From Investing Activities -77.00K -$45.00K -58.00K
Cash From Financing Activities 4.812M $6.748M 3.642M
Net Change In Cash -160.0K $1.103M -530.0K
YoY Change -95.54% -136.84% -90.98%
FREE CASH FLOW
Cash From Operating Activities -$4.895M -$5.600M -$4.114M
Capital Expenditures $77.00K $45.00K $58.00K
Free Cash Flow -$4.972M -$5.645M -$4.172M
YoY Change -25.77% -4.09% -25.33%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-38659
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
BIOSIG TECHNOLOGIES, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-4333375
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
55 Greens Farms Road, 1st Floor
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Westport
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CT
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
06880
CY2023Q1 dei City Area Code
CityAreaCode
203
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
409-5444
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
BSGM
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
70485322 shares
CY2023Q1 us-gaap Cash
Cash
1412000 usd
CY2022Q4 us-gaap Cash
Cash
357000 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
17000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
345000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
336000 usd
CY2023Q1 us-gaap Sales Type Lease Lease Receivable
SalesTypeLeaseLeaseReceivable
101000 usd
CY2022Q4 us-gaap Sales Type Lease Lease Receivable
SalesTypeLeaseLeaseReceivable
101000 usd
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
275000 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
325000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
2150000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1128000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
630000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
665000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
634000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
705000 usd
CY2023Q1 us-gaap Inventory Noncurrent
InventoryNoncurrent
1142000 usd
CY2022Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
1141000 usd
CY2023Q1 us-gaap Sales Type And Direct Financing Leases Lease Receivable
SalesTypeAndDirectFinancingLeasesLeaseReceivable
94000 usd
CY2022Q4 us-gaap Sales Type And Direct Financing Leases Lease Receivable
SalesTypeAndDirectFinancingLeasesLeaseReceivable
120000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
303000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
307000 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
244000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
44000 usd
CY2023Q1 us-gaap Assets
Assets
5197000 usd
CY2022Q4 us-gaap Assets
Assets
4110000 usd
CY2023Q1 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
0 usd
CY2022Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
120000 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2392000 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2852000 usd
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8000 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
0 usd
CY2023Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0 usd
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
5000 usd
CY2023Q1 us-gaap Dividends Payable Current
DividendsPayableCurrent
93000 usd
CY2022Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
91000 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
321000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
313000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2814000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3261000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
368000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
452000 usd
CY2023Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
368000 usd
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
452000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
3182000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
3713000 usd
CY2023Q1 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
105 shares
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
105 shares
CY2023Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
105 shares
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
105 shares
CY2023Q1 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
105000 usd
CY2022Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
105000 usd
CY2023Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
105000 usd
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
105000 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
66857687 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
66857687 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54610638 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54610638 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
67000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
55000 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
225215000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
216232000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-223306000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-215974000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1976000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
313000 usd
CY2023Q1 us-gaap Minority Interest
MinorityInterest
-66000 usd
CY2022Q4 us-gaap Minority Interest
MinorityInterest
-21000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1910000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
292000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5197000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4110000 usd
CY2023Q1 us-gaap Revenues
Revenues
5000 usd
CY2022Q1 us-gaap Revenues
Revenues
8000 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1062000 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1617000 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6245000 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6401000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
84000 usd
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
55000 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
7391000 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
8073000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7386000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8065000 usd
CY2023Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
4000 usd
CY2022Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
0 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7382000 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8065000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-7382000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-8065000 usd
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-50000 usd
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-102000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7332000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7963000 usd
CY2023Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
2000 usd
CY2022Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
2000 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7334000 usd
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7965000 usd
CY2023Q1 bsgm Earnings Per Share Basic And Diluted1
EarningsPerShareBasicAndDiluted1
-0.12
CY2022Q1 bsgm Earnings Per Share Basic And Diluted1
EarningsPerShareBasicAndDiluted1
-0.22
CY2023Q1 bsgm Weighted Average Number Of Share Outstanding Basic And Diluted1
WeightedAverageNumberOfShareOutstandingBasicAndDiluted1
61426514 shares
CY2022Q1 bsgm Weighted Average Number Of Share Outstanding Basic And Diluted1
WeightedAverageNumberOfShareOutstandingBasicAndDiluted1
35997298 shares
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
292000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1097000 usd
CY2023Q1 bsgm Stock Value Issued In Settlement Of Debt
StockValueIssuedInSettlementOfDebt
105000 usd
CY2023Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
482000 usd
CY2023Q1 us-gaap Stockholders Equity Other
StockholdersEquityOther
6748000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1052000 usd
CY2023Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
2000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-7382000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1910000 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
12460000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1601000 usd
CY2022Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
15000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
399000 usd
CY2022Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
2000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-8065000 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9410000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-7382000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-8065000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
84000 usd
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
55000 usd
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
71000 usd
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
85000 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2149000 usd
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2000000 usd
CY2023Q1 us-gaap Equity Fair Value Adjustment
EquityFairValueAdjustment
0 usd
CY2022Q1 us-gaap Equity Fair Value Adjustment
EquityFairValueAdjustment
-15000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 usd
CY2023Q1 us-gaap Increase Decrease In Leasing Receivables
IncreaseDecreaseInLeasingReceivables
-25000 usd
CY2022Q1 us-gaap Increase Decrease In Leasing Receivables
IncreaseDecreaseInLeasingReceivables
0 usd
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
9000 usd
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
145000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
151000 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-43000 usd
CY2023Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-5000 usd
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-8000 usd
CY2023Q1 us-gaap Increase Decrease In Deposits
IncreaseDecreaseInDeposits
8000 usd
CY2022Q1 us-gaap Increase Decrease In Deposits
IncreaseDecreaseInDeposits
0 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-355000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
165000 usd
CY2023Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-75000 usd
CY2022Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-86000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5648000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5941000 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
45000 usd
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
55000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-45000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-55000 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6748000 usd
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3002000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6748000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3002000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1055000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2994000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
357000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11659000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1412000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8665000 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2023Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2022Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2023Q1 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
105000 usd
CY2022Q1 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
0 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
2000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
2000 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1400000 usd
CY2023Q1 bsgm Working Capital Deficit
WorkingCapitalDeficit
-700000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5600000 usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Use of Estimates</i></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of these unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, stock-based compensation and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2022Q4 us-gaap Property Subject To Or Available For Operating Lease Number Of Units
PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits
2 pure
CY2022 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
4333 usd
CY2022Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P30Y
CY2022Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P1Y
CY2022 bsgm Lessor Sales Type Lease Discount Rate
LessorSalesTypeLeaseDiscountRate
0.02 pure
CY2023Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0 usd
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
5000 usd
CY2023Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
0 usd
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
0 usd
CY2023Q1 us-gaap Deferred Revenue
DeferredRevenue
0 usd
CY2022Q4 us-gaap Deferred Revenue
DeferredRevenue
5000 usd
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
CY2022Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Concentrations of Credit Risk</i></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such amounts may be in excess of the FDIC insurance limit. At March 31, 2023 and December 31, 2022, deposits in excess of FDIC limits were $1.1 million and $0.05 million, respectively.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2023Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
1100000 usd
CY2022Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
50000.00 usd
CY2023Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1487000 usd
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1477000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
345000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
336000 usd
CY2023Q1 us-gaap Inventory Noncurrent
InventoryNoncurrent
1142000 usd
CY2022Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
1141000 usd
CY2023Q1 us-gaap Deposit Assets
DepositAssets
200000 usd
CY2022Q4 us-gaap Deposit Assets
DepositAssets
0 usd
CY2023Q1 us-gaap Security Deposit
SecurityDeposit
43000 usd
CY2022Q4 us-gaap Security Deposit
SecurityDeposit
43000 usd
CY2023Q1 us-gaap Indefinite Lived Trademarks
IndefiniteLivedTrademarks
1000 usd
CY2022Q4 us-gaap Indefinite Lived Trademarks
IndefiniteLivedTrademarks
1000 usd
CY2023Q1 us-gaap Other Assets
OtherAssets
244000 usd
CY2022Q4 us-gaap Other Assets
OtherAssets
44000 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1100000 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1600000 usd
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14429756 shares
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8546658 shares
CY2023Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
4851 usd
CY2022Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
4751 usd
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1311000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1266000 usd
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
681000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
601000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
630000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
665000 usd
CY2023Q1 us-gaap Depreciation
Depreciation
79468 usd
CY2022Q1 us-gaap Depreciation
Depreciation
50082 usd
CY2023Q1 bsgm Number Of Leases
NumberOfLeases
2 pure
CY2023Q1 bsgm Operating Lease Right To Use Assets Gross
OperatingLeaseRightToUseAssetsGross
995000 usd
CY2022Q4 bsgm Operating Lease Right To Use Assets Gross
OperatingLeaseRightToUseAssetsGross
995000 usd
CY2023Q1 bsgm Operating Lease Right To Use Asset Accumulated Depreciation
OperatingLeaseRightToUseAssetAccumulatedDepreciation
361000 usd
CY2022Q4 bsgm Operating Lease Right To Use Asset Accumulated Depreciation
OperatingLeaseRightToUseAssetAccumulatedDepreciation
290000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
634000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
705000 usd
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
92081 usd
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
107734 usd
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
689000 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
765000 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
321000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
313000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
368000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
452000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
268000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
370000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
106000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
744000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
55000 usd
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
689000 usd
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
71000 usd
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
85000 usd
CY2023Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
6000 usd
CY2022Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
9000 usd
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
15000 usd
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
14000 usd
CY2023Q1 us-gaap Lease Cost
LeaseCost
92000 usd
CY2022Q1 us-gaap Lease Cost
LeaseCost
108000 usd
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
4333 usd
CY2022Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P30M
CY2022Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P1Y
CY2022Q3 bsgm Lessor Sales Type Lease Discount Rate
LessorSalesTypeLeaseDiscountRate
0.02 pure
CY2023Q1 us-gaap Sales Type Lease Unguaranteed Residual Asset
SalesTypeLeaseUnguaranteedResidualAsset
4000 usd
CY2022Q4 us-gaap Sales Type Lease Net Investment In Lease
SalesTypeLeaseNetInvestmentInLease
221000 usd
CY2023Q1 us-gaap Sales Type Lease Revenue
SalesTypeLeaseRevenue
0 usd
CY2023Q1 bsgm Sales Type Lease Invoiced To Customer
SalesTypeLeaseInvoicedToCustomer
-30000 usd
CY2023Q1 us-gaap Sales Type Lease Interest Income Lease Receivable
SalesTypeLeaseInterestIncomeLeaseReceivable
0 usd
CY2023Q1 us-gaap Sales Type Lease Unguaranteed Residual Asset
SalesTypeLeaseUnguaranteedResidualAsset
4000 usd
CY2023Q1 us-gaap Sales Type Lease Net Investment In Lease
SalesTypeLeaseNetInvestmentInLease
195000 usd
CY2023Q1 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Next Twelve Months
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths
78000 usd
CY2023Q1 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Two Years
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears
104000 usd
CY2023Q1 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Three Years
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears
13000 usd
CY2023Q1 us-gaap Sales Type Lease Unguaranteed Residual Asset
SalesTypeLeaseUnguaranteedResidualAsset
4000 usd
CY2023Q1 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived
199000 usd
CY2023Q1 us-gaap Sales Type And Direct Financing Leases Lease Receivable Undiscounted Excess Amount
SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount
4000 usd
CY2023Q1 us-gaap Sales Type Lease Net Investment In Lease
SalesTypeLeaseNetInvestmentInLease
195000 usd
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
735000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
646000 usd
CY2023Q1 bsgm Accrued Reimbursements Current
AccruedReimbursementsCurrent
77000 usd
CY2022Q4 bsgm Accrued Reimbursements Current
AccruedReimbursementsCurrent
33000 usd
CY2023Q1 bsgm Accrued Consulting Current
AccruedConsultingCurrent
530000 usd
CY2022Q4 bsgm Accrued Consulting Current
AccruedConsultingCurrent
546000 usd
CY2023Q1 bsgm Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
187000 usd
CY2022Q4 bsgm Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
625000 usd
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
33000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
0 usd
CY2023Q1 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
96000 usd
CY2022Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
256000 usd
CY2023Q1 bsgm Accrued Office Expense And Other Expense
AccruedOfficeExpenseAndOtherExpense
169000 usd
CY2022Q4 bsgm Accrued Office Expense And Other Expense
AccruedOfficeExpenseAndOtherExpense
220000 usd
CY2023Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
552000 usd
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
513000 usd
CY2023Q1 us-gaap Settlement Liabilities Current
SettlementLiabilitiesCurrent
13000 usd
CY2022Q4 us-gaap Settlement Liabilities Current
SettlementLiabilitiesCurrent
13000 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2392000 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2852000 usd
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022 bsgm Deemed Preferred Stock Dividend
DeemedPreferredStockDividend
209682 usd
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
66857687 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54610638 shares
CY2022 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
2370000 shares
CY2022 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1060740 usd
bsgm Class Of Warrant Or Rights Granted
ClassOfWarrantOrRightsGranted
400525 shares
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.7884
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P6M
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4052945 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4616151 shares
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M12D
CY2023Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
3268952 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4555484 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.49
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M12D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
3000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
250000 shares
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.25
CY2023Q1 bsgm Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted In Period Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm
P10Y
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
189333 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
5.23
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4616151 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.3
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M12D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
184520
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3268952 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.98
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
125750 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
257187 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
649992 usd
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1270896 usd
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
8867786 shares
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.7884
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P6M
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4217111 shares
CY2022Q4 bsgm Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Outstanding
ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsOutstanding
1.89
CY2022Q4 bsgm Warrants Outstanding Weighted Average Remaining Contractual Term
WarrantsOutstandingWeightedAverageRemainingContractualTerm
P4Y3M18D
CY2022Q4 bsgm Class Of Warrant Or Rights Outstanding Intrinsic Value
ClassOfWarrantOrRightsOutstandingIntrinsicValue
3960 usd
CY2023Q1 bsgm Class Of Warrant Or Rights Granted
ClassOfWarrantOrRightsGranted
4650675 shares
CY2023Q1 bsgm Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Granted
ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsGranted
0.79
CY2023Q1 bsgm Warrants Granted Weighted Average Remaining Contractual Term
WarrantsGrantedWeightedAverageRemainingContractualTerm
P5Y4M24D
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
8867786 shares
CY2023Q1 bsgm Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Outstanding
ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsOutstanding
1.31
CY2023Q1 bsgm Warrants Outstanding Weighted Average Remaining Contractual Term
WarrantsOutstandingWeightedAverageRemainingContractualTerm
P4Y9M18D
CY2023Q1 bsgm Class Of Warrant Or Rights Vested And Expected To Vest Outstanding
ClassOfWarrantOrRightsVestedAndExpectedToVestOutstanding
8867786 shares
CY2023Q1 bsgm Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Vested And Expected To Vest Outstanding
ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsVestedAndExpectedToVestOutstanding
1.31
CY2023Q1 bsgm Warrants Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term
WarrantsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm
P4Y9M18D
CY2023Q1 bsgm Class Of Warrant Or Rights Vested And Expected To Vest Outstanding Intrinsic Value
ClassOfWarrantOrRightsVestedAndExpectedToVestOutstandingIntrinsicValue
2699954 usd
CY2023Q1 bsgm Class Of Warrant Or Rights Exercisable
ClassOfWarrantOrRightsExercisable
3026123 shares
CY2023Q1 bsgm Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Exercisable
ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsExercisable
2.46
CY2023Q1 bsgm Warrants Exercisable Weighted Average Remaining Contractual Term
WarrantsExercisableWeightedAverageRemainingContractualTerm
P3Y7M6D
CY2023Q1 bsgm Class Of Warrant Or Rights Exercisable Intrinsic Value
ClassOfWarrantOrRightsExercisableIntrinsicValue
235450 usd
CY2023Q1 us-gaap Share Price
SharePrice
1.14
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
the exercise price of an Incentive Stock Option should not be less than 110% of fair market value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair market value for a grantee who is not 10% stockholder
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2650071 shares
CY2022Q4 us-gaap Minority Interest
MinorityInterest
-21000 usd
CY2023Q1 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Sale Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesSaleOfInterestByParent
5000 usd
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-50000 usd
CY2023Q1 us-gaap Minority Interest
MinorityInterest
-66000 usd
CY2023Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
65919 usd
CY2022Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
67640 usd
CY2023Q1 us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
2546694 usd
CY2023Q1 us-gaap Revenues
Revenues
5000 usd
CY2022Q1 us-gaap Revenues
Revenues
8000 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
7391000 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
8073000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7386000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8065000 usd
CY2023Q1 us-gaap Assets
Assets
5197000 usd
CY2022Q1 us-gaap Assets
Assets
4110000 usd
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
0 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
120000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P5Y6M
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P5Y6M
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001530766

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
bsgm-20230331_cal.xml Edgar Link unprocessable
0001185185-23-000516-index-headers.html Edgar Link pending
0001185185-23-000516-index.html Edgar Link pending
0001185185-23-000516.txt Edgar Link pending
0001185185-23-000516-xbrl.zip Edgar Link pending
biosig20230331_10q.htm Edgar Link pending
bsgm-20230331.xsd Edgar Link pending
bsgm-20230331_def.xml Edgar Link unprocessable
bsgm-20230331_pre.xml Edgar Link unprocessable
bsgm-20230331_lab.xml Edgar Link unprocessable
biosig20230331_10q_htm.xml Edgar Link completed
ex_518513.htm Edgar Link pending
ex_518514.htm Edgar Link pending
ex_518515.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending